Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia

被引:46
作者
Arriazu, Elena [1 ]
Pippa, Raffaella [2 ]
Odero, Maria D. [1 ,3 ,4 ]
机构
[1] Univ Navarra, Ctr Appl Med Res CIMA, Hematol Oncol Program, E-31080 Pamplona, Spain
[2] Univ Dundee, Ctr Gene Regulat & Express, Dundee, Scotland
[3] Univ Navarra, Dept Biochem & Genet, E-31080 Pamplona, Spain
[4] Inst Invest Sanitaria Navarra IdiSNA, Pamplona, Spain
来源
FRONTIERS IN ONCOLOGY | 2016年 / 6卷
关键词
PP2A; SET; AML; FTY720; OP449; CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR PP2A; REGULATORY SUBUNIT B55-ALPHA; TYROSINE KINASE INHIBITORS; A-BETA-SUBUNIT; BREAST-CANCER; C-MYC; COMMON EVENT; SET-CAN; CIP2A;
D O I
10.3389/fonc.2016.00078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive advances in our understanding of the molecular biology of this disease, the outcome for most patients is poor. It is, therefore, necessary to develop more effective treatment strategies. Genetic aberrations affecting kinases have been widely studied in AML; however, the role of phosphatases remains underexplored. Inactivation of the tumor-suppressor protein phosphatase 2A (PP2A) is frequent in AML patients, making it a promising target for therapy. There are several PP2A inactivating mechanisms reported in this disease. Deregulation or specific post-translational modifications of PP2A subunits have been identified as a cause of PP2A malfunction, which lead to deregulation of proliferation or apoptosis pathways, depending on the subunit affected. Likewise, overexpression of either SET or cancerous inhibitor of protein phosphatase 2A, endogenous inhibitors of PP2A, is a recurrent event in AML that impairs PP2A activity, contributing to leukemogenesis progression. Interestingly, the anticancer activity of several PP2A-activating drugs (PADs) depends on interaction/sequestration of SET. Preclinical studies show that pharmacological restoration of PP2A activity by PADs effectively antagonizes leukemogenesis, and that these drugs have synergistic cytotoxic effects with conventional chemotherapy and kinase inhibitors, opening new possibilities for personalized treatment in AML patients, especially in cases with SET-dependent inactivation of PP2A. Here, we review the role of PP2A as a druggable tumor suppressor in AML.
引用
收藏
页数:11
相关论文
共 118 条
  • [21] CIP2A Is Associated with Human Breast Cancer Aggressivity
    Come, Christophe
    Laine, Anni
    Chanrion, Maia
    Edgren, Henrik
    Mattila, Elina
    Liu, Xiaoling
    Jonkers, Jos
    Ivaska, Johanna
    Isola, Jorma
    Darbon, Jean-Marie
    Kallioniemi, Olli
    Thezenas, Simon
    Westermarck, Jukka
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (16) : 5092 - 5100
  • [22] PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect
    Cristobal, I.
    Garcia-Orti, L.
    Cirauqui, C.
    Alonso, M. M.
    Calasanz, M. J.
    Odero, M. D.
    [J]. LEUKEMIA, 2011, 25 (04) : 606 - 614
  • [23] Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
    Cristobal, Ion
    Rincon, Raul
    Manso, Rebeca
    Carames, Cristina
    Zazo, Sandra
    Madoz-Gurpide, Juan
    Rojo, Federico
    Garcia-Foncillas, Jesus
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (02) : 347 - 356
  • [24] Cristóbal I, 2013, HAEMATOLOGICA, V98, pE103, DOI [10.3324/haematol.2013.084731, 10.3324/haematol.2043.084731]
  • [25] Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia
    Cristobal, Ion
    Garcia-Orti, Laura
    Cirauqui, Cristina
    Cortes-Lavaud, Xabier
    Garcia-Sanchez, Maria A.
    Calasanz, Maria J.
    Odero, Maria D.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (04): : 543 - 550
  • [26] SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia
    Cristobal, Ion
    Blanco, Francisco J.
    Garcia-Orti, Laura
    Marcotegui, Nerea
    Vicente, Carmen
    Rifon, Jose
    Novo, Francisco J.
    Bandres, Eva
    Calasanz, Maria J.
    Bernabeu, Carmelo
    Odero, Maria D.
    [J]. BLOOD, 2010, 115 (03) : 615 - 625
  • [27] Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia
    de Mendoza, A. Estella-Hermoso
    Castello-Cros, R.
    Imbuluzqueta, E.
    Cirauqui, C.
    Pippa, R.
    Odero, M. D.
    Blanco-Prieto, M. J.
    [J]. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 2015, 11 (04) : 691 - 701
  • [28] Acute Myeloid Leukemia
    Doehner, Hartmut
    Weisdorf, Daniel J.
    Bloomfield, Clara D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (12) : 1136 - 1152
  • [29] CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis
    Dong, Qian-Ze
    Wang, Yang
    Dong, Xin-Jun
    Li, Zi-Xuan
    Tang, Zhong-Ping
    Cui, Quan-Ze
    Wang, En-Hua
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (03) : 857 - 865
  • [30] Protein phosphatase 2A regulatory subunits and cancer
    Eichhorn, Pieter J. A.
    Creyghton, Menno P.
    Bernards, Rene
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2009, 1795 (01): : 1 - 15